Global Hydroxycarbamide Market Strategic Research Report

Scope of the Report

The global Hydroxycarbamide market size is predicted to grow from US$ 281 million in 2025 to US$ 406 million in 2032; it is expected to grow at a CAGR of 5.5% from 2026 to 2032.

Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.

Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.

Global Hydroxycarbamide key players include Qilu Pharmaceutical, Beijing Jialin Pharma, Taj Pharma, etc. Global top three manufacturers hold a share over 35%.

Asia-Pacific is the largest market, with a share nearly 60%, followed by Europe, and North America, both have a share about 40 percent.

In terms of product, Capsule is the largest segment, with a share over 60%. And in terms of application, the largest application is Sickle Cell Disease, followed by Cancer, etc.

This report presents a comprehensive overview of the global Hydroxycarbamide market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Capsule
• Tablet

Segment by Application

• Sickle Cell Disease
• Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Hydroxycarbamide market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Sickle Cell Disease, Cancer, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact